$1.46 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 5 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SYBX | SYNLOGIC INC | $494,000 | -0.8% | 205,906 | 0.0% | 33.77% | +17.2% | |
| GNCA | GENOCEA BIOSCIENCES INC | $469,000 | +7.8% | 375,000 | 0.0% | 32.06% | +27.4% | |
| AADI BIOSCIENCES INC | $453,000 | -29.7% | 26,666 | 0.0% | 30.96% | -16.9% | ||
| IDRA | IDERA PHARMACEUTICALS INC | $28,000 | -12.5% | 56,250 | 0.0% | 1.91% | +3.4% | |
| NABRIVA THERAPEUTICS PLC | $19,000 | -29.6% | 45,849 | 0.0% | 1.30% | -16.8% | ||
| LUNG | Exit | PULMONX CORP | $0 | – | -2,901 | -100.0% | -5.38% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNLOGIC INC | 12 | Q3 2023 | 33.8% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 37.2% |
| IDERA PHARMACEUTICALS INC | 9 | Q4 2022 | 2.4% |
| GENOCEA BIOSCIENCES INC | 8 | Q3 2022 | 32.1% |
| NABRIVA THERAPEUTICS PLC | 7 | Q2 2022 | 2.3% |
| CASTLE BIOSCIENCES INC | 6 | Q3 2023 | 77.2% |
| PULMONX CORP | 5 | Q4 2021 | 33.9% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 2.3% |
| ATEA PHARMACEUTICALS INC | 2 | Q2 2021 | 91.0% |
| ATEA PHARMACEUTICALS INC | 1 | Q1 2021 | 80.1% |
View ABG Innovation Capital Partners III GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View ABG Innovation Capital Partners III GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.